Bone Cancer Diagnosis Market Size, Share, Diagnostic Trends & Forecast 2035

Bone Cancer Diagnosis Market Size and Forecast 2035

The global bone cancer diagnosis market reached USD 1.33 billion in 2025 and is projected to reach around USD 2.20 billion by 2035, expanding at a CAGR of 5.2% during 2026-2035.

Primary bone cancer remains rare. In the United States, SEER estimates 4,110 new bone and joint cancer cases and 2,210 deaths in 2026, with a five-year relative survival of 68.7% for cases diagnosed during 2016-2022.

The market opportunity is larger than incidence alone suggests because diagnosing a malignant bone lesion usually requires several sequential technologies rather than a single test. X-ray may identify the initial abnormality; MRI defines local tumor extent; CT evaluates cortical bone and the lungs; PET/CT or bone scintigraphy assists staging; and biopsy with expert pathology establishes the definitive diagnosis. NCI emphasizes that biopsy remains essential and should be planned carefully because the biopsy tract can affect subsequent limb-sparing surgery.

The next growth phase is shifting toward AI-assisted imaging, fusion-defined molecular pathology, quantitative MRI, whole-body PET, and liquid-biopsy research.

Bone Cancer Diagnosis Market Highlights

• 2025 Market Size: USD 1.33 Billion
• 2035 Forecast Market Size: USD 2.20 Billion
• CAGR, 2026-2035: 5.2%
• Largest Region: North America - 38.6% share
• Fastest-Growing Region: Asia-Pacific
• Leading Diagnostic Modality: MRI - 29.8% share
• Leading Cancer Type by Diagnostic Revenue: Osteosarcoma - 34.2% share
• Leading End User: Hospitals - 49.5% share

Bone Cancer Diagnosis Market Definition

Primary bone cancer refers to malignant tumors originating in bone rather than cancers that begin elsewhere and subsequently metastasize to the skeleton.

The principal primary malignant bone tumors covered in this report are osteosarcoma, chondrosarcoma, Ewing sarcoma and chordoma, together with rarer malignant bone neoplasms.

NCI distinguishes primary bone cancer from secondary bone metastases, which retain the name and biological identity of the organ where the cancer began.

The diagnostic market includes imaging, tissue acquisition, histopathology and molecular testing required to identify and characterize suspected malignant bone tumors, determine local extent, detect metastatic spread and guide treatment planning.

The market also captures adjacent demand generated when the same imaging technologies are used to assess suspicious malignant bone lesions in broader oncology workflows. Epidemiological estimates for primary bone cancer and secondary bone metastasis should nevertheless remain separate.

White-Space Opportunity: From Tissue Diagnosis to Molecularly Defined Bone Sarcoma

The biggest diagnostic shift is occurring after the biopsy specimen reaches pathology.

Historically, bone sarcomas were classified largely according to appearance under the microscope, immunohistochemistry, and anatomical context.

That approach is no longer sufficient for several important tumors.

Ewing sarcoma is increasingly a fusion-defined diagnosis. NCI explains that widespread genomic testing has changed classification of small round cell sarcomas and now distinguishes classic Ewing sarcoma from tumors carrying EWSR1 non-ETS fusions, CIC rearrangements and BCOR genetic alterations.

The best-known molecular event, EWSR1-FLI1, occurs in 90% of Ewing sarcomas according to SEER's current pediatric molecular-data specification. The National Childhood Cancer Registry now records EWSR1 fusion status for contemporary pediatric cases, illustrating how molecular pathology is moving into routine cancer classification and registry infrastructure.

Chondrosarcoma creates another molecular opportunity. NCI notes that selected tumors can contain alterations involving IDH1, IDH2, COL2A1, and EWSR1-associated fusions, depending on subtype.

The commercial implication is that the future bone-cancer diagnostic pathway is unlikely to end at “biopsy positive for sarcoma.”

Bone Cancer Diagnosis Market Strategic Takeaways

MRI remains the leading modality and is estimated to account for 29.8% of 2025 diagnostic-market revenue, broadly retaining the 29.6% leadership position reported by DataM Intelligence for 2024.

North America retains 38.6% of global revenue, equivalent to roughly USD 512 million in 2025. The region's position reflects advanced MRI, CT, PET and pathology capacity together with highly specialized orthopedic-oncology and pediatric sarcoma centers.

Asia-Pacific is the fastest-growing region. DataM Intelligence previously reported 21.4% regional share; the refreshed 2025 model places APAC at 22.1% as diagnostic infrastructure continues to expand.

Osteosarcoma generates an estimated 34.2% of diagnostic-market revenue, supported by intensive MRI, pulmonary CT, biopsy, pathology and staging requirements. NCI describes osteosarcoma as occurring predominantly in adolescents and young adults, with an estimated incidence of 5.4 cases per million annually among people aged 0-19 years in the United States.

Ewing sarcoma is particularly important to molecular diagnostics because correct classification increasingly requires identification of characteristic gene fusions rather than morphology alone.

AI is moving from research into commercial bone-lesion detection. In March 2025, Guerbet and Intrasense announced CE marking under the EU Medical Device Regulation for DUOnco Bone, an AI system designed to automatically detect and localize bone lesions on thoraco-abdomino-pelvic CT scans.

Liquid biopsy remains investigational rather than a replacement for tissue biopsy, but active 2026 sarcoma trials are evaluating ctDNA for diagnosis, prognosis, response assessment and recurrence monitoring.

Bone Cancer Diagnosis Market Trends and Strategic Insights

MRI Remains the Center of Local Tumor Assessment

MRI is difficult to displace in primary bone sarcoma because diagnosis requires more than identifying that a bone abnormality exists.

Clinicians need to understand intramedullary tumor extent, soft-tissue involvement, relationship to neurovascular structures and the presence of additional tumor deposits along the affected bone.

NCI includes MRI of the primary tumor site in the standard diagnostic evaluation for Ewing sarcoma and describes MRI as part of the imaging workup for osteosarcoma and other primary bone malignancies.

Advanced diffusion imaging, accelerated acquisition and quantitative imaging should strengthen MRI's role rather than replace it.

Philips' May 2026 Titanion research platform illustrates the direction of travel. The company is developing ultra-high-gradient 3.0T MRI to enable whole-body quantitative and microstructural biomarkers, although Philips explicitly states that Titanion remains work in progress and is not yet FDA cleared or CE marked.

The commercial opportunity lies in shorter acquisition, quantitative tumor characterization and more reproducible assessment of treatment response.

AI Is Moving Into Bone-Lesion Detection

Bone lesions can be difficult to identify when radiologists must review hundreds or thousands of CT images generated during routine oncology staging.

In March 2025, Guerbet and Intrasense announced CE marking for DUOnco Bone, designed to analyze thorax-abdomen-pelvis CT examinations automatically and return three-dimensional coordinates for suspicious bone lesions.

The product is particularly relevant to bone metastasis detection rather than being a stand-alone diagnostic test for osteosarcoma or Ewing sarcoma.

Its importance to this market is nevertheless strategic.

AI-assisted bone-lesion detection demonstrates how image interpretation itself is becoming a purchasable diagnostic technology rather than merely a professional service performed after a scanner generates images.

Future bone-cancer platforms could extend this model toward tumor segmentation, differential diagnosis, biopsy targeting and longitudinal treatment-response assessment.

PET Is Shifting Toward Faster Whole-Body Imaging

PET/CT plays an important role in staging selected bone sarcomas and detecting metabolically active disease.

NCI includes PET among staging modalities for osteosarcoma and Ewing sarcoma. For Ewing sarcoma, NCI notes that many investigators consider PET capable of replacing conventional bone scintigraphy in appropriate staging settings.

Technology development is making PET increasingly compatible with whole-body oncology workflows.

GE HealthCare received CE marking in November 2025 for its Omni 128 cm total-body PET/CT, designed for head-to-thigh imaging in one bed position and for reduced scan times and dose compared with conventional multi-position acquisition.

Siemens Healthineers received U.S. FDA clearance in January 2026 for the Biograph One PET/MR, which combines functional PET information and high-resolution MRI in a single system and incorporates AI-supported reconstruction and workflow automation.

These platforms are not bone-cancer-specific, but their whole-body oncology capabilities are relevant to staging rare sarcomas where both local anatomy and distant metastatic assessment matter.

PET/MR Could Be Particularly Relevant to Young Patients

Bone sarcomas frequently affect children, adolescents and young adults.

That makes radiation exposure an unusually important imaging consideration.

MRI does not use ionizing radiation, while PET/MR can provide metabolic and anatomical information without the CT component used in PET/CT.

Siemens states that its Biograph One is designed to combine PET and MRI with reduced examination time compared with its prior PET/MR generation.

PET/MR remains a premium and relatively specialized modality, but pediatric oncology provides one of the clinical environments where combining functional imaging with reduced radiation exposure may have long-term value.

Tissue Biopsy Cannot Yet Be Replaced

AI, PET and liquid biopsy are expanding, but histological confirmation remains the decisive diagnostic step for suspected primary malignant bone tumors.

NCI describes core needle or open biopsy as the basis for osteosarcoma diagnosis and stresses that the procedure should be planned by clinicians experienced in bone-tumor surgery because an incorrectly positioned biopsy tract can compromise later limb-sparing surgery.

The same principle applies broadly across bone sarcoma.

This creates durable demand for image-guided core biopsy systems, pathology services, immunohistochemistry and molecular laboratories.

It also explains why the fastest scan does not necessarily create the greatest diagnostic value. The commercial winner must improve the entire pathway from lesion detection to definitive tumor classification.

Liquid Biopsy Is Moving Into Prospective Sarcoma Studies

Circulating tumor DNA is one of the most important emerging diagnostic technologies, but it should not yet be presented as a routine replacement for tissue biopsy.

A Wake Forest-led study updated in July 2026 is prospectively evaluating low-pass whole-genome sequencing of blood in adult and pediatric bone and soft-tissue sarcomas.

The study explicitly examines whether ctDNA can support diagnosis, prognosis, treatment-response assessment, minimal residual disease detection and recurrence monitoring.

A separate NCI-sponsored osteosarcoma Phase II/III study is collecting ctDNA at diagnosis and during therapy. The protocol evaluates whether baseline ctDNA burden and subsequent changes correlate with event-free-survival risk.

NCI has also reported that detectable Ewing-sarcoma fusion ctDNA at diagnosis has been associated with inferior outcomes in retrospective and trial-linked analyses.

The commercial opportunity through 2035 is therefore more likely to begin in monitoring and risk stratification before liquid biopsy becomes an independent primary diagnostic tool.

Bone Cancer Diagnosis Market Scope

Bone Cancer Diagnosis Market Disruption Analysis

The first disruption is the movement from image detection to computational image interpretation.

Traditional imaging economics were centered on scanners, contrast media and professional radiology interpretation.

AI adds another monetizable layer.

DUOnco Bone's 2025 CE marking demonstrates how an algorithm can become a regulated component of the bone-lesion diagnostic workflow, automatically analyzing CT data before or alongside the radiologist.

The second disruption is the movement from morphological pathology to molecularly defined sarcoma classification.

Ewing sarcoma is the clearest example. NCI's modern classification separates several morphologically similar round-cell sarcomas according to specific gene fusions and molecular alterations.

This increases demand for FISH, RT-PCR, targeted sequencing, and broader NGS where morphology and immunohistochemistry cannot reliably establish tumor identity.

The third disruption involves disease monitoring.

Repeated CT, MRI, and PET remain standard methods for assessing treatment response and recurrence, but ctDNA could eventually provide a complementary blood-based signal of residual disease.

The current NCI osteosarcoma study and Wake Forest sarcoma liquid-biopsy study show that this transition is already being tested prospectively.

Bone Cancer Diagnosis Market Dynamics

Rare Disease Still Requires High Diagnostic Intensity

Bone cancer accounts for only a small percentage of total malignancies.

SEER projects just over 4,000 bone and joint cancer cases in the United States during 2026.

However, each suspicious case may generate X-ray, MRI, chest CT, PET or bone scan, image-guided biopsy, expert pathology and molecular testing.

That high number of diagnostic touchpoints supports a market substantially larger than incidence alone might imply.

Pediatric and Young-Adult Disease Supports Advanced Imaging

Osteosarcoma and Ewing sarcoma disproportionately affect younger patients.

NCI describes osteosarcoma as occurring predominantly in adolescents and young adults, while Ewing sarcoma has particularly high relevance in children and adolescents.

This creates demand for MRI, dose-efficient PET, pediatric anesthesia workflows and imaging strategies that minimize unnecessary ionizing radiation.

Accurate Biopsy Planning Has Direct Treatment Consequences

Bone-tumor biopsy is not simply a laboratory sampling procedure.

NCI warns that biopsy placement can influence later surgical options, and inappropriate placement or contamination can interfere with limb-preserving reconstruction.

That creates a strong rationale for biopsy at specialized sarcoma centers and for image-guided techniques planned jointly by radiologists, orthopedic oncologists and pathologists.

Molecular Complexity Expands Laboratory Spending

Morphologically similar bone tumors may represent biologically different diseases.

Ewing sarcoma, CIC-rearranged sarcoma, BCOR-altered sarcoma and EWSR1 non-ETS fusion tumors illustrate this diagnostic complexity.

As treatment trials become more molecularly specific, accurate classification becomes commercially more valuable.

High Equipment Cost Restricts Emerging-Market Adoption

MRI, PET/CT, PET/MR and advanced pathology require substantial capital, infrastructure and specialist expertise.

The existing DMI report identifies the cost of advanced diagnostic testing and specialized equipment as a major market restraint.

Whole-body PET and advanced 3T MRI can improve diagnostic capabilities, but these platforms are more difficult to deploy in lower-volume markets where rare bone tumors may not justify dedicated infrastructure.

Scarcity of Expert Pathologists Can Delay Diagnosis

Rare bone tumors create a diagnostic-volume problem.

A general pathology department may encounter relatively few osteosarcomas, Ewing sarcomas or chordomas compared with common epithelial cancers.

Because classification can determine surgery, chemotherapy and clinical-trial eligibility, difficult cases frequently benefit from specialist sarcoma-pathology review.

This creates growing demand for digital pathology, remote consultation and centralized molecular testing.

Bone Cancer Diagnosis Market Segment Analysis

MRI Leads with 29.8% Market Share

MRI is estimated to account for 29.8% of global bone cancer diagnostic revenue in 2025, representing roughly USD 395 million.

The share remains close to DataM Intelligence's reported 29.6% leadership position in 2024.

MRI's primary advantage is its ability to characterize bone marrow and soft tissue without ionizing radiation.

For osteosarcoma and Ewing sarcoma, it helps define the longitudinal and soft-tissue extent of the primary tumor and contributes directly to biopsy and surgical planning. NCI includes MRI as part of the standard diagnostic evaluation for these tumors.

MRI should remain the largest modality through 2035, although its commercial model will increasingly include AI reconstruction, quantitative biomarkers and automated segmentation rather than scanner hardware alone.

CT Accounts for 21.9%

CT represents an estimated 21.9% of 2025 market revenue, or about USD 290 million.

CT has several roles.

It provides detailed assessment of cortical bone, can guide biopsy and is fundamental to evaluation of pulmonary metastases, particularly in osteosarcoma and Ewing sarcoma.

The emerging growth area is AI-assisted CT interpretation.

DUOnco Bone demonstrates the potential to automatically identify suspicious bone lesions during routine oncology CT, adding a software-revenue layer to conventional CT imaging.

Biopsy, Histopathology and Molecular Testing Account for 19.7%

Biopsy and pathology are estimated to represent 19.7% of the market, equal to around USD 261 million in 2025.

This segment includes image-guided tissue acquisition, conventional pathology, immunohistochemistry and molecular confirmation.

Its share is expected to increase because definitive sarcoma classification is becoming progressively more dependent on molecular information.

Ewing sarcoma provides the strongest example: NCI's contemporary framework distinguishes several small round cell sarcomas through specific genetic alterations that cannot be resolved reliably through imaging alone.

X-Ray Accounts for 15.5%

X-ray represents an estimated 15.5% of global diagnostic revenue, or USD 205 million.

It remains one of the first imaging tests ordered when a patient presents with persistent bone pain, swelling, or a suspicious lesion.

NCI states that X-rays can show a bone tumor's location, size and shape and often trigger subsequent advanced imaging when findings are suspicious.

The low cost and wide availability of radiography ensure that it remains a major diagnostic-volume modality even as revenue growth shifts toward MRI, molecular testing and AI.

PET/CT and Bone Scintigraphy Account for 13.1%

PET/CT, bone scintigraphy and related staging techniques represent 13.1% of the 2025 market, around USD 174 million.

Their commercial role is weighted toward staging rather than initial local diagnosis.

NCI lists PET and bone scan among staging options for osteosarcoma and Ewing sarcoma. In Ewing sarcoma, PET increasingly provides an alternative to conventional bone scintigraphy in some clinical pathways.

The category could gain value from faster total-body PET systems and combined PET/MR platforms despite the small primary bone-cancer population.

Osteosarcoma Generates 34.2% of Diagnostic Revenue

Osteosarcoma is estimated to account for 34.2% of the 2025 bone cancer diagnosis market, equal to around USD 453 million.

It is especially important commercially because its diagnostic pathway combines local MRI, chest CT, biopsy, pathology, and metastatic staging.

NCI estimates an osteosarcoma incidence of 5.4 per million annually in U.S. patients aged 0-19 years.

The disease also represents an important liquid-biopsy development opportunity. The active NCI osteosarcoma trial is prospectively evaluating ctDNA at diagnosis, before surgery, and after surgery as a possible prognostic and response biomarker.

Chondrosarcoma Accounts for 27.1%

Chondrosarcoma is estimated to generate 27.1% of market revenue, around USD 359 million.

Unlike osteosarcoma and Ewing sarcoma, it predominantly affects adults.

NCI estimates U.S. incidence at one case per 200,000 people per year and identifies CT, MRI and biopsy as central elements of diagnosis.

Molecular testing is becoming more relevant because different chondrosarcoma subtypes can contain alterations such as IDH1/2, COL2A1 or specific gene fusions.

Ewing Sarcoma Represents 21.4%

Ewing sarcoma accounts for an estimated 21.4% of global diagnostic revenue, USD 284 million.

Its share exceeds what might be expected from case numbers alone because diagnosis and staging are unusually intensive.

Standard evaluation can include primary-site MRI, chest CT, PET, X-ray, laboratory testing and tissue biopsy.

Molecular confirmation provides additional value because EWSR1-associated fusion testing helps differentiate classic Ewing sarcoma from other round-cell sarcomas.

Chordoma Accounts for 8.3%

Chordoma represents an estimated 8.3% of diagnostic-market value, USD 110 million.

Although rare, chordomas often arise at complex anatomical sites such as the skull base or spine.

Their location increases reliance on high-resolution MRI, CT, specialist pathology and multidisciplinary diagnostic review.

Other Bone Tumors Represent 9.0%

Other malignant primary bone tumors contribute 9.0% of the market, equivalent to around USD 119 million.

These include rarer sarcoma subtypes and malignant tumors that require expert pathological differentiation from the major bone-cancer categories.

Hospitals Are the Largest End User

Hospitals are estimated to account for 49.5% of global diagnostic revenue in 2025, representing around USD 656 million.

Their leadership reflects the need to coordinate imaging, biopsy, pathology, anesthesia and specialist orthopedic oncology.

Independent and hospital-affiliated diagnostic imaging centers represent 31.8%, around USD 422 million, with MRI, CT and PET accounting for most revenue.

Dedicated cancer centers, pediatric oncology centers and sarcoma research institutes represent 14.1%, while other diagnostic settings account for around 4.6%.

Bone Cancer Diagnosis Market Geographical Analysis

North America Leads with 38.6% Market Share

North America is estimated to account for 38.6% of global bone cancer diagnostic revenue in 2025, or around USD 512 million.

This retains the market share reported in DataM Intelligence's current analysis.

The region benefits from broad MRI and CT access, advanced pediatric oncology, specialist sarcoma centers, molecular pathology laboratories and high utilization of PET imaging.

The United States is estimated to hold 33.8% of global market revenue, or around USD 448 million.

SEER expects 4,110 new bone and joint cancer cases in the U.S. during 2026.

Although incidence is low, patients frequently undergo several advanced diagnostic procedures, supporting comparatively high spending per case.

The U.S. is also an important innovation market. Siemens Healthineers received FDA clearance for its second-generation Biograph One PET/MR in January 2026, while NCI-sponsored studies are actively evaluating ctDNA as a biomarker in newly diagnosed osteosarcoma.

Canada is estimated to contribute 3.1% of global revenue, while Mexico accounts for 1.7%.

Europe accounts for 27.4%

Europe is estimated to represent 27.4% of global bone cancer diagnosis revenue in 2025, around USD 363 million.

The region combines mature radiology infrastructure with established sarcoma referral networks and broad access to MRI and pathology.

Germany represents an estimated 5.3% of global market revenue, making it the largest modeled European country market.

The United Kingdom accounts for 4.6%, France around 4.1%, Italy 2.8%, and Spain roughly 2.4%.

Europe is also becoming an important commercialization market for AI-assisted lesion detection.

The March 2025 MDR CE marking of Guerbet and Intrasense's DUOnco Bone represents one of the clearest examples of regulated AI entering bone-lesion CT interpretation.

GE HealthCare's Omni 128 cm total-body PET/CT received CE marking in November 2025, strengthening the region's access to high-sensitivity whole-body molecular imaging.

Asia-Pacific Is the Fastest-Growing Region

Asia-Pacific is estimated to account for 22.1% of global revenue in 2025, equal to around USD 293 million.

The existing DataM Intelligence analysis already identifies APAC as the fastest-growing region and reported a 21.4% share.

Growth is being driven by wider MRI and CT installation, expanding oncology infrastructure and improving referral pathways for pediatric and orthopedic cancers.

China is estimated to hold 6.6% of global revenue, making it the largest Asia-Pacific country market.

The country is increasing access to advanced imaging and has become an important research market for AI-assisted MRI and cancer-image analysis.

Japan represents 4.2% of global revenue, supported by high-end imaging infrastructure and mature oncology services.

India accounts for an estimated 3.3%. Its opportunity is strongly linked to improving timely referral of children and young adults with persistent bone pain or suspicious radiographic findings to specialist sarcoma centers.

South Korea contributes 2.0%, while Australia represents around 1.8%.

The region's long-term opportunity will depend not simply on installing scanners but on connecting imaging with expert biopsy, pathology and molecular confirmation.

Latin America Represents 6.7%

Latin America is estimated to contribute 6.7% of global bone cancer diagnostic revenue in 2025, around USD 89 million.

Brazil accounts for an estimated 3.0% of global revenue and is the region's largest market.

Advanced MRI and pathology are available in large metropolitan cancer centers, but referral delays and uneven access to specialist orthopedic oncology remain commercial constraints across parts of the region.

Argentina contributes 0.9%, with the remaining Latin American countries accounting for 2.8%.

Expansion of regional pediatric-cancer networks, digital pathology and MRI capacity should gradually improve access to definitive diagnosis.

Middle East & Africa Account for 5.2%

Middle East & Africa represent an estimated 5.2% of global diagnostic revenue, USD 69 million.

Saudi Arabia and the UAE are the strongest premium diagnostic markets in the Gulf, supported by investment in tertiary hospitals, MRI, PET/CT and precision oncology.

South Africa remains one of the principal specialist sarcoma-diagnostic markets in Sub-Saharan Africa.

Across lower-resource countries, diagnostic delays may result from limited MRI access, lack of specialist musculoskeletal radiologists and insufficient sarcoma pathology expertise.

Digital pathology, centralized molecular testing and tele-radiology could partially address these geographic gaps through 2035.

Bone Cancer Diagnosis Competitive Landscape

Competition in this market is moving beyond scanner manufacturing.

The future competitive structure combines imaging hardware, AI interpretation, molecular pathology and integrated oncology workflow software.

Siemens Healthineers maintains a broad position across MRI, CT, digital X-ray, PET/CT and PET/MR.

In January 2026, the company received FDA clearance for Biograph One, its second-generation PET/MR platform. The system combines anatomical and metabolic imaging and uses AI-based reconstruction and workflow automation.

GE HealthCare competes across MRI, CT, PET/CT, SPECT/CT and advanced visualization.

Its Omni 128 cm total-body PET/CT obtained CE marking in November 2025 and is designed to improve whole-body cancer diagnosis, staging and treatment planning through higher-sensitivity imaging and shorter acquisition.

Philips maintains an important MRI and CT position.

Its 2026 Titanion MR research platform illustrates the company's direction toward quantitative whole-body imaging biomarkers and AI-supported MRI, although the system is not yet commercially cleared.

Guerbet and Intrasense occupy a more differentiated software position through DUOnco Bone.

The 2025 CE-marked product automatically detects and localizes suspicious bone lesions on CT and represents a direct commercial example of dedicated AI for bone-lesion interpretation.

Canon Medical Systems and Fujifilm Healthcare remain relevant through MRI, CT and diagnostic-imaging platforms used across oncology and musculoskeletal care.

The molecular-diagnostic side remains more fragmented, involving specialist pathology laboratories, NGS providers and academic sarcoma reference centers rather than a single dominant bone-cancer testing franchise.

Company Positioning

Multimodality Imaging Leaders: Siemens Healthineers, GE HealthCare, Philips, Canon Medical and Fujifilm compete through MRI, CT, X-ray, PET and integrated imaging ecosystems.

Bone-Lesion AI Specialist: Guerbet/Intrasense currently provides one of the clearest dedicated commercial AI propositions through DUOnco Bone.

Molecular Diagnostic Opportunity: Specialized NGS, FISH and molecular-pathology laboratories are becoming more important as fusion-driven sarcoma classification expands.

Liquid-Biopsy Opportunity: The category remains development-stage rather than established commercial standard of care, but current prospective studies provide a route toward blood-based monitoring and risk assessment.

Recent Bone Cancer Diagnosis Market Developments

• July 28, 2026: The NCI-sponsored Phase II/III osteosarcoma study evaluating cabozantinib with chemotherapy remained recruiting. Beyond treatment efficacy, the protocol incorporates ctDNA measurements at diagnosis and throughout therapy to assess prognostic and response value.
• July 23, 2026: A Wake Forest-led prospective liquid-biopsy study remained recruiting and continued evaluating low-pass whole-genome sequencing for ctDNA detection across adult and pediatric bone and soft-tissue sarcomas.
• May 11, 2026: Philips introduced the Titanion ultra-high-gradient 3.0T MRI research platform for quantitative and microstructural imaging. The technology remains work in progress rather than a cleared commercial product.
• January 29, 2026: Siemens Healthineers received FDA clearance for Biograph One PET/MR, combining digital PET with 3T MRI and AI-supported reconstruction for oncology and other imaging applications.
• November 28, 2025: GE HealthCare announced CE marking for its Omni 128 cm total-body PET/CT, designed for head-to-thigh imaging in a single bed position and for advanced cancer diagnosis, staging and research.
• March 18, 2025: Guerbet and Intrasense announced CE marking under MDR for DUOnco Bone, an AI system dedicated to detecting and localizing bone lesions on thoraco-abdomino-pelvic CT examinations.

Bone Cancer Diagnostic Workflow and Procurement Priorities

Clinical suspicion and first-line imaging remain the beginning of the pathway.

Persistent localized bone pain, swelling or a suspicious radiographic abnormality generally triggers additional imaging rather than immediate definitive diagnosis.

MRI quality is a major procurement consideration because local tumor extent directly influences biopsy and limb-sparing surgical planning.

Chest CT capability is important because the lungs are a major metastatic site for bone sarcomas such as osteosarcoma and Ewing sarcoma. NCI includes chest CT in standard Ewing diagnostic evaluation.

Biopsy planning must be coordinated with the surgical team. The cheapest or fastest biopsy is not necessarily the best option if the tract compromises later resection.

Pathology expertise matters because rare bone tumors can mimic one another morphologically.

Molecular-testing capability is increasingly necessary for small round cell sarcomas and selected chondrosarcoma subtypes.

Pediatric dose management influences PET and CT purchasing because many osteosarcoma and Ewing patients are young.

Workflow integration is becoming another differentiator. Hospitals increasingly evaluate whether imaging, AI, PACS, pathology and oncology systems can exchange diagnostic information without creating separate manual workflows.

Strategic Opportunity Areas Through 2035

AI-Assisted Bone-Lesion Detection

Commercial AI is beginning to address a real radiology problem: bone lesions may be overlooked on large oncology CT datasets.

DUOnco Bone demonstrates a regulatory and commercial pathway for dedicated bone-lesion algorithms.

Fusion-Based Sarcoma Diagnosis

Molecular classification of Ewing and related round-cell sarcomas creates continued demand for FISH, RT-PCR and NGS.

The more treatment trials differentiate tumors according to fusion biology, the greater the value of exact molecular classification.

ctDNA Monitoring

Liquid biopsy is unlikely to eliminate diagnostic tissue biopsy in the near term.

Its stronger initial opportunity is likely to be risk assessment, early response monitoring and recurrence surveillance.

Current prospective sarcoma and osteosarcoma studies support this direction.

Whole-Body PET and PET/MR

Faster whole-body PET and combined PET/MR may improve staging workflows, particularly when clinicians need both local anatomical detail and whole-body metabolic assessment.

Recent Siemens and GE platform launches demonstrate continuing investment in this category.

Quantitative MRI

MRI can evolve from visual tumor measurement toward quantitative biomarkers of tissue microstructure and treatment response.

The 2026 Philips Titanion research platform illustrates the technology direction, though commercial availability remains pending.

Digital Sarcoma Pathology

Because primary bone cancers are rare, many community hospitals have limited exposure to individual sarcoma subtypes.

Digital slide sharing, remote second opinions and centralized molecular analysis can connect local hospitals with specialist sarcoma pathologists without requiring every facility to maintain the same expertise.

Why Choose DataM Intelligence?

DataM Intelligence evaluates the bone cancer diagnosis market as an integrated imaging-pathology-molecular diagnostics pathway rather than treating it as an MRI equipment market alone.

The report quantifies MRI, CT, X-ray, biopsy/pathology and nuclear-imaging demand across osteosarcoma, chondrosarcoma, Ewing sarcoma, chordoma and other malignant bone tumors.

It examines why molecular classification is becoming essential in Ewing and related round-cell sarcomas and how this change affects pathology and NGS demand.

The study tracks commercial AI developments such as DUOnco Bone while distinguishing algorithms designed for bone-lesion detection from definitive primary bone-cancer diagnosis.

Pipeline analysis evaluates ctDNA as an emerging monitoring and prognostic technology while avoiding the premature assumption that liquid biopsy can replace tissue diagnosis.

Regional analysis combines imaging infrastructure, specialist sarcoma-center access and molecular-testing capabilities to identify where diagnostic-market growth is most likely through 2035.

Target Audience

Diagnostic-imaging manufacturers, MRI and CT companies, PET and nuclear-medicine companies, AI radiology developers, pathology laboratories, molecular-diagnostic and NGS companies, image-guided biopsy manufacturers, hospitals, orthopedic-oncology centers, pediatric cancer centers, radiology networks, contract research organizations, healthcare investors, business-development teams and academic sarcoma research groups.